Insmed Incorporated (NASDAQ: INSM) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
120.00
-3.98-3.21%
News
Down 3.2% — Tracking Baker Brothers' Portfolio: Q2 2026 Update (SeekingAlpha).
Medium confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -4.11 | Insider Own | 1.06% | Shs Outstand | 216.75M | Perf Week | -7.27% |
| Market Cap | 26.01B | Forward P/E | 145.22 | EPS next Y | 0.83 | Insider Trans | -26.63% | Shs Float | 198.42M | Perf Month | -8.16% |
| Enterprise Value | 26.05B | PEG | - | EPS next Q | -0.37 | Inst Own | - | Short Float | 5.77% | Perf Quarter | 25.26% |
| Income | -873.94M | P/S | 22.86 | EPS this Y | 60.99% | Inst Trans | - | Short Ratio | 3.36 | Perf Half Y | -16.67% |
| Sales | 1.14B | P/B | 34.43 | EPS next Y | 151.54% | ROA | -41.63% | Short Interest | 11.44M | Perf YTD | -31.05% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -111.26% | 52W High | 212.77 -43.60% | Perf Year | -17.12% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -48.85% | 52W Low | 90.39 32.76% | Perf 3Y | 356.27% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 35.24% 29.88% | Gross Margin | 83.27% | Volatility | 4.52% 3.80% | Perf 5Y | 341.99% |
| Dividend TTM | - | EV/Sales | 22.89 | EPS Y/Y TTM | 26.21% | Oper. Margin | -71.86% | ATR (14) | 5.16 | Perf 10Y | 761.45% |
| Dividend Ex-Date | - | Quick Ratio | 3.40 | Sales Y/Y TTM | 212.36% | Profit Margin | -76.94% | RSI (14) | 46.02 | Recom | 2.09 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.72 | EPS Q/Q | 96.47% | SMA20 | -3.34% | Beta | 0.82 | Target Price | 196.93 |
| Payout | 0.00% | Debt/Eq | 0.77 | Sales Q/Q | 297.20% | SMA50 | 1.45% | Rel Volume | 1.29 | Prev Close | 123.98 |
| Employees | 1,664 | LT Debt/Eq | 1.01 | Earnings | Oct 29 | SMA200 | -12.55% | Avg Volume | 2.67M | Price | 120.00 |
| IPO Date | Jun 01, 2000 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 91.08% 7.58% | Net Debt/EBITDA | -0.05 | Volume | 3,429,712 | Change | -3.21% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-15-26 | Reiterated | Roth Capital | Buy | $212 → $198 |
| Aug-10-26 | Reiterated | Truist Securities | Buy | $185 → $195 |
| Aug-07-26 | Reiterated | Morgan Stanley | Overweight | $212 → $218 |
| Aug-07-26 | Reiterated | UBS | Buy | $166 → $172 |
| Aug-07-26 | Reiterated | Guggenheim | Buy | $226 → $205 |
| Aug-07-26 | Reiterated | Wells Fargo | Overweight | $161 → $169 |
| Aug-07-26 | Reiterated | Evercore ISI Group | Outperform | $180 → $170 |
| Aug-06-26 | Reiterated | Jefferies | Buy | $160 → $175 |
| Jul-28-26 | Reiterated | Cantor Fitzgerald | Overweight | $230 → $235 |
| Jul-20-26 | Initiated | BMO Capital | Outperform | $192 |
Latest News· Times ET
Sep-16-26
03:00AM
Sep-14-26
Sep-14-2604:31PM
Sep-10-26
Sep-09-26
Sep-09-2606:27AM
Sep-08-26
Sep-04-26
Sep-03-26
Sep-03-2603:00AM
Aug-31-26
Aug-31-2610:57AM
Aug-27-26
Aug-26-26
02:45AM
Aug-25-26
Aug-24-26
Aug-24-2603:00AM
Aug-23-26
Company
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,137 | 606 | 364 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 190 | 125 | 86 | — | — | — | — | — | — | |
| Gross Profit | 947 | 482 | 278 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 892 | 701 | 461 | — | — | — | — | — | — | |
| Research and Development | 860 | 771 | 598 | — | — | — | — | — | — | |
| Other Operating Expense | 13 | 186 | 97 | — | — | — | — | — | — | |
| Operating Income | -818 | -1,177 | -878 | — | — | — | — | — | — | |
| Interest Expense | 81 | 84 | 85 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 29 | -11 | 53 | — | — | — | — | — | — | |
| Net Income Before Taxes | -869 | -1,272 | -910 | — | — | — | — | — | — | |
| Income Taxes | 6 | 5 | 4 | — | — | — | — | — | — | |
| Consolidated Net Income | -875 | -1,277 | -914 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -875 | -1,277 | -914 | — | — | — | — | — | — | |
| Net Income | -875 | -1,277 | -914 | — | — | — | — | — | — | |
| EPS (Recurring) | -4.11 | -6.41 | -5.57 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -4.11 | -6.41 | -5.57 | — | — | — | — | — | — | |
| EPS (Diluted) | -4.11 | -6.41 | -5.57 | — | — | — | — | — | — | |
| EBITDA | -770 | -1,172 | -819 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 22.90 | 61.46 | 31.11 | — | — | — | — | — | — | |
| Gross Margin | 83.29 | 79.54 | 76.37 | — | — | — | — | — | — | |
| Operating Margin | -71.94 | -194.22 | -241.21 | — | — | — | — | — | — | |
| Net Margin | -76.96 | -210.73 | -251.10 | — | — | — | — | — | — | |
| Shares Outstanding | 217 | 214 | 164 | — | — | — | — | — | — | |
| Market Capitalization | 26,040 | 37,245 | 11,323 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Brennan David R | Director | Sep 09 '26 | Sale | 124.00 | 25,000 | 3,100,000 | 39,238 | Sep 11 |
| SHAROKY MELVIN MD | Director | Aug 17 '26 | Sale | 127.53 | 5,000 | 637,650 | 0 | Aug 19 |
| Adsett Roger | Chief Operating Officer | Aug 10 '26 | Option Exercise | 20.45 | 239,850 | 4,905,570 | 338,594 | Aug 12 |
| Adsett Roger | Chief Operating Officer | Aug 10 '26 | Sale | 133.27 | 239,850 | 31,964,810 | 98,744 | Aug 12 |
| Flammer Martina M.D. | Chief Medical Officer | Aug 06 '26 | Option Exercise | 21.20 | 27,173 | 576,126 | 87,659 | Aug 07 |
| Flammer Martina M.D. | Chief Medical Officer | Aug 06 '26 | Sale | 128.61 | 27,173 | 3,494,838 | 60,486 | Aug 07 |
| Lewis William | Chair and CEO | Jul 23 '26 | Option Exercise | 24.94 | 10,700 | 266,870 | 269,758 | Jul 24 |
| Lewis William | Chair and CEO | Jul 23 '26 | Sale | 106.06 | 10,700 | 1,134,890 | 259,058 | Jul 24 |
| Lewis William | Chair and CEO | Jul 09 '26 | Option Exercise | 24.94 | 10,699 | 266,839 | 269,757 | Jul 10 |
| Lewis William | Chair and CEO | Jul 09 '26 | Sale | 117.40 | 10,699 | 1,256,085 | 259,058 | Jul 10 |
| Flammer Martina M.D. | Chief Medical Officer | Jul 06 '26 | Option Exercise | 25.80 | 12,302 | 317,445 | 72,788 | Jul 08 |
| Flammer Martina M.D. | Chief Medical Officer | Jul 06 '26 | Sale | 109.98 | 12,302 | 1,352,932 | 60,486 | Jul 08 |
| Lewis William | Chair and CEO | Jun 25 '26 | Sale | 103.32 | 21,398 | 2,210,763 | 258,917 | Jun 26 |
| Lewis William | Chair and CEO | Jun 25 '26 | Option Exercise | 24.94 | 21,398 | 533,679 | 280,315 | Jun 26 |
| Smith Michael Alexander | Chief Legal Officer | Jun 22 '26 | Sale | 95.82 | 1,806 | 173,051 | 37,648 | Jun 24 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.